estrogen positive breast cancer recurrence rates

Release time ：Nov-17,2024

The recurrence rate for estrogen receptor-positive breast cancer typically peaks within the first five years post-treatment and then declines gradually. This subtype of breast cancer is more responsive to hormonal therapy, meaning prompt treatment can significantly mitigate the risk of recurrence. In detail, for patients undergoing adjuvant endocrine therapy, the recurrence rate is approximately 2% in the first year, with a yearly decrease of about 0.5%. Beyond the five-year mark, the rate drops to roughly 1% annually. Nonetheless, a small subset of patients may still face recurrence in the years following the completion of the standard five-year endocrine therapy regimen. Thus, ongoing surveillance and periodic follow-ups are essential for the early detection of any recurrence. For individuals with estrogen receptor-positive breast cancer, adhering to the treatment plan and recommendations provided by their healthcare provider is crucial. Additionally, maintaining a healthy lifestyle that includes a balanced diet, regular exercise, and stress management can further reduce the likelihood of recurrence. Should any symptoms suggestive of recurrence arise, such as the appearance of new lumps or persistent pain, it is imperative to seek immediate medical attention and a professional evaluation.